Ipsen's Latest Consumer Health Play: Growth Or Attracting Suitors?
This article was originally published in The Pink Sheet
Less than a month after investing in Italian nutritional supplement maker Akkadeas Pharma, Ipsen acquires five Sanofi OTC drug brands marketed in Europe, including Prontalgine analgesics available in France.
You may also be interested in...
Ipsen CEO David Loew has kicked off a strategic review of the company's "non core" Consumer Healthcare business, which has endured a particularly tough year thanks to the COVID-19 pandemic.
Hypera has agreed to pay BRL1.3bn to acquire the rights in Brazil to Buscopan and Buscofem from Boehringer Ingelheim.
Sanofi consumer products head Alan Main says BI's brands will "lift Sanofi into leadership positions in attractive OTC categories, namely the vitamins and minerals supplements market, digestive products, cough and cold as well as pain medications."